CHICAGO, June 1 /PRNewswire/ -- Researchers at the Barbara Ann Karmanos
Cancer Institute in Detroit today presented findings that show
immunotherapy with armed targeted T cells may improve the overall survival
of women with metastatic breast cancer.
(Logo:
http://www.newscom.com/cgi-bin/prnh/20071106/KARMANOSCANCERINSTITUTELOG
O )
Abstract 3034, Phase I immunotherapy in women with metastatic breast
cancer with activated T cells targeted with anti-CD-3 x anti-Her2/neu
bispecific antibody, was given at the American Society of Clinical Oncology
Annual Meeting in Chicago.
The study's goal was to determine whether the patients' T cells, armed
with an antibody, could be expanded and used safely to attack the tumor,
said Lawrence Lum, M.D., D.Sc., Scientific Director of BMT and
Immunotherapy, Professor of Medicine at Karmanos Cancer Institute and the
Wayne State University School of Medicine.
According to Dr. Lum, preclinical studies showed that anti-CD3
activated T cells (ATC) can be expanded and retargeted or armed with
anti-CD3x anti-Her2 bispecific antibody (HER2Bi). The studies demonstrated
that Her2B-armed ATC expand, divide, and exhibit high levels of
cytotoxicity directed at breast cancer cells and secrete cytokines
essential for boosting immune responses to tumors.
Seventeen patients, aged 31 - 86, were treated with eight infusions
twice a week for four weeks with 5, 10, 20 and 40 billion ATC doses (armed
with Her2Bi) to determine the maximum dosage tolerated. T cells from
leukopheresis were activated and expanded with anti-CD3/IL-2 for 14 days,
harvested, armed with Her2Bi, and cryopreserved. IL-2 (3 x 105 IU/m2/daily)
and GM-CSF (250 micrograms/m2 twice a week) were given three days prior to
the first infusion and ended one week after the last infusion.
"The results suggest that this treatment modality may improve overall
survival for metastatic breast cancer," Dr. Lum said. "Although high
numbers of remissions were not induced, we may have improved the patients'
longevity and quality of life without undue toxicities. The predominant
side effects were chills, fever, headaches, and transient hypotension that
were controlled with medications and fluid support."
"It appears that infusions of targeted T cells have boosted the immune
system to create a more efficient tumor killing machine within the
patient's body," he said. "Although the median survival rate for all
patients remains undefined, survival rates for the HER2 (0-2+) cohort is
21.3 months." He said that the immunotherapy may be vaccinating the
patient's immune system to their own tumors. This is encouraging given that
the tumor burden was high in the majority of women who had failed other
therapies and the prognosis is poor.
In addition to Dr. Lum, abstract authors include: Zaid Al-Kadhimi,
M.D., Associate Director of Immunotherapy, Karmanos Cancer Institute;
Cassara Skuba, B.S., Supervisor of Cell Processing Facility, Karmanos
Cancer Institute; Rebecca Sandborg, Ph.D., Karmanos Cancer Institute;
Ritesh Rathore, M.D., Chief of Hematology/Oncology, Assistant Professor of
Medicine, Boston University, Roger Williams Hospital, Providence, RI; Qin
Liu, Ph.D., Assistant Professor of Medicine, University of Massachusetts,
Worcester, MA; and Co-Leaders of the Karmanos Cancer Center BMT
Multidisciplinary team Voravit Ratanatharathorn, M.D. and Joseph Uberti,
M.D., Ph.D.
The Phase I Clinical Trial was supported by a National Cancer Institute
ROI CA92344 grant, a translational grant from the Leukemia & Lymphoma
Society Michigan Life Science Grant, funds from Roger Williams Hospital,
Providence RI and funds from the Karmanos Cancer Institute.
The Barbara Ann Karmanos Cancer Institute
The Barbara Ann Karmanos Cancer Institute in Detroit is one of 41
National Cancer Institute (NCI)-designated comprehensive cancer centers in
the United States. Caring for more than 6,000 new patients annually on a
budget of 16 million, conducting more than 700 cancer-specific scientific
investigation programs and clinical trials, the Karmanos Cancer Institute
is among the nation's best cancer centers. Its Phase I Clinical Trials
Program is one of only 16 NCI funded programs in the country. Through the
commitment of 1,000 staff, including nearly 300 faculty members, and
supported by thousands of volunteer and financial donors, the Institute
strives to prevent, detect and eradicate all forms of cancer. John C.
Ruckdeschel, M.D., is the Institute's president and chief executive
officer. For more information call 1-800-KARMANOS or go to
http://www.karmanos.org.
American Society of Clinical Oncology
ASCO is the world's leading professional organization representing
physicians who care for people with cancer. With more than 25,000 members,
ASCO is committed to improving cancer care through scientific meetings,
educational programs and peer-reviewed journals. For ASCO information and
resources, visit http://www.asco.org/presscenter.
See Also
- Scrubs & Beyond Showcases Dickies Medical Uniforms For Cool, Comfortable Summer Work Days
- Lake Mohawk Gallery of Emryn International LLC will be Featuring the Oil and Pastel Paintings of Laurie Harden
- Boots No7 for Men Launches Fake Tan to Help Men Banish Pale and Pasty Bodywork
- What to Expect During a Breast Surgery Consultation
Via: Healthcare
0 коментарі:
Post a Comment